1. Home
  2. AIRT vs EQ Comparison

AIRT vs EQ Comparison

Compare AIRT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

HOLD

Current Price

$21.93

Market Cap

58.6M

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.01

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRT
EQ
Founded
1980
2017
Country
United States
United States
Employees
646
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AIRT
EQ
Price
$21.93
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.00
AVG Volume (30 Days)
1.8K
380.2K
Earning Date
02-13-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.05
$0.29
52 Week High
$26.70
$2.70

Technical Indicators

Market Signals
Indicator
AIRT
EQ
Relative Strength Index (RSI) 47.54 56.24
Support Level $20.85 $1.65
Resistance Level $23.82 $2.30
Average True Range (ATR) 0.58 0.18
MACD -0.01 0.01
Stochastic Oscillator 40.79 85.26

Price Performance

Historical Comparison
AIRT
EQ

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: